User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.
The post and conversation are about a 23-year-old deciding to stop using finasteride for hair loss due to potential erectile dysfunction risks, sparking a debate about the benefits and side effects of hair loss treatments.
The user has been taking finasteride for a year without improvement and added minoxidil and dermarolling recently, but hair loss continues. Blood tests showed normal testosterone and vitamins, except for low vitamin D3 and an allergy, which doctors suggested could be causing the hair loss.
The conclusion of the conversation is that the user, BreadButterCoffee, did not have success with dutasteride for hair loss and found better results with a combination of finasteride, minoxidil, and microneedling. They recommend trying microneedling for those who have been on medication for years with minimal improvement.
A user experienced a significant drop in testosterone levels after taking finasteride, leading to side effects like low libido and muscle mass loss. Despite its effectiveness for hair, the user decided to stop finasteride due to its impact on hormones, preferring to be bald.
A 27-year-old male started using topical finasteride (0.25%) and minoxidil (5%) once daily, along with supplements like zinc, magnesium, biotin, and vitamins C and D. After initial concerns about side effects, he experienced temporary ED and shedding but now feels better and has no regrets about starting the treatment.
The conversation discusses the side effects of finasteride, including low libido and erectile dysfunction, and the possibility of these effects being permanent, known as post-finasteride syndrome (PFS). Some users report personal experiences with PFS and debate whether the condition is real, with varying opinions on the reversibility of side effects and the role of individual biology.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.